BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Sanofi’s $3.68 Billion Buy Not Paying Off Yet as Autoimmune Drug Flunks Phase III

  Paris-based Sanofi announced its Phase III PEGASUS clinical trial of rilzabrutinib for pemphigus failed to hit primary or key secondary endpoints.

  September 9, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Research Roundup: Young Adults with COVID-19 Have Unaffected Lung Function and More

  Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

  September 9, 2021

   · 

  6 min read

   · 

  Mark Terry
• 

  Business

  Evommune Closes Series A Round Worth $83 Million

  Los Altos, Calif.-based Evommune closed on a Series A financing round worth $83 million. The financing round included Andera Partners, LSP, Pivotal bioVenture Partners.

  September 9, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  BioSpace Movers & Shakers, Sept. 10

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

  September 9, 2021

   · 

  8 min read

   · 

  Alex Keown
• 

  Deals

  Roche Bolsters Diagnostics Division with Acquisition of Longtime Partner

  The procurement will expand its PCR-test portfolio capabilities in the ongoing fight against existing and emerging infectious diseases, including new COVID-19 variants of interest.

  September 9, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  FDA

  Humanigen Stock Craters After FDA Rejects COVID-19 Therapeutic

  The FDA stated that it could not determine if the use of lenzilumab in COVID patients outweighs the known and potential safety risks.

  September 9, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  RNA Editor ProQR Lines Up $1.5 Billion Deal with Eli Lilly

  The partnership combines the companies’ resources to focus on Axiomer, a technology that can edit single nucleotides in RNA in a specific and highly targeted manner.

  September 9, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Biotech Bay

  Investors Pour $360 Million into Cutting-Edge Biotechs

  Obsidian Therapeutics and three other pharmaceutical companies announced successful Series B raises to propel pipeline candidates further down the track toward clinical studies and approvals.

  September 9, 2021

   · 

  3 min read

   · 

  Kate Goodwin
• 

  Career Advice

  Post-COVID Career Planning - What Does It Include?

  Looking for a career boost? Here are a few practical tips to progress in the post-COVID career landscape.

  September 9, 2021

   · 

  2 min read

   · 

  Brandi Marcene
• 

  Drug Development

  Moderna’s mRNA Pipeline Shows No Sign of Slowing Down on R&D Day

  This week, the mRNA leader followed up its announcement of a collaboration with the Institute for Life Changing Medicines (ILCM), with an update on several programs advancing in its pipeline.

  September 9, 2021

   · 

  5 min read

   · 

  Heather McKenzie